Point of care testing of phospholipase A2 group IIA for serological diagnosis of rheumatoid arthritis

摘要

Secretory phospholipase A2 group IIA (sPLA(2)-IIA) was examined as a point of care marker for determining disease activity in rheumatoid (RA) and psoriatic (PsA) arthritis. Serum concentration and activity of sPLA(2)-IIA were measured using in-house antibodies and a novel point of care lateral flow device assay in patients diagnosed with varying severities of RA (n = 30) and PsA (n = 25) and found to correlate strongly with C-reactive protein (CRP). Levels of all markers were elevated in patients with active RA over those with inactive RA as well as both active and inactive PsA, indicating that sPLA(2)-IIA can be used as an analogue to CRP for RA diagnosis at point of care.